3SBio Inc.

HKSE 1530.HK

3SBio Inc. Operating Income Margin for the year ending December 31, 2023: 31.45%

3SBio Inc. Operating Income Margin is 31.45% for the year ending December 31, 2023, a -9.50% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

3SBio Inc. Operating Income Margin for the year ending December 31, 2022 was 34.75%, a 13.01% change year over year.
3SBio Inc. Operating Income Margin for the year ending December 31, 2021 was 30.75%, a 39.50% change year over year.
3SBio Inc. Operating Income Margin for the year ending December 31, 2020 was 22.05%, a -12.23% change year over year.
3SBio Inc. Operating Income Margin for the year ending December 31, 2019 was 25.12%, a -20.26% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

HKSE: 1530.HK

3SBio Inc.

CEO	Dr. Jing Lou M.D., Ph.D.
IPO Date	June 11, 2015
Location	China
Headquarters	No. 3 A1, Road 10
Employees	5,607
Sector	Healthcare
Industries Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals Plastics Vaccines

Description

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Key trends

Past 5 years